BTIG has revised its price target for DexCom (DXCM, Financial), reducing it to $107 from the previous $120, while maintaining a Buy rating on the stock. This adjustment comes as part of a broader analysis of the upcoming first-quarter results within the MedTech sector.
The MedTech industry has been perceived as a relatively secure investment area; however, current market conditions suggest that future strategies might be more impactful on company performance than the immediate quarterly outcomes. Challenges such as the ongoing trade tensions predominantly affecting China, alongside federal healthcare budget cuts, are factors that could influence investor sentiment in the sector.
Given the uncertain environment, investor attention is likely to focus on how well companies can adapt and navigate these external pressures, which could result in volatility in the sector's stocks, including DexCom.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $101.72 with a high estimate of $120.00 and a low estimate of $80.00. The average target implies an upside of 53.80% from the current price of $66.14. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $174.20, suggesting a upside of 163.38% from the current price of $66.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
